Volume 11, Number 3, March 2005

Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes

Nigel J. Temperton,* Paul K. Chan,† Graham Simmons,‡ Maria C. Zambon,§ Richard S. Tedder,* Yasuhiro Takeuchi,* and Robin A. Weiss*
*University College London, London, United Kingdom; †Prince of Wales Hospital, Shatin, New Territories, Hong Kong Special Administrative Region, People's Republic of China; ‡University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA; and §Health Protection Agency Central Public Health Laboratory, London, United Kingdom

Figure 2. Correlation of neutralizing antibody titers measured by plaque reduction assay with titers measured with pseudotype assay. LV, neutralizing antibody titer by using replication-competent severe acute respiratory syndrome–associated coronavirus (SARS-CoV) (live virus); PV, neutralizing antibody titer by using pseudotype virus; PV₉₀ (filled black diamonds), 90% neutralizing antibody titer by using murine leukemia virus (MLV) (SARS) pseudotype virus; PV₅₀ (open squares), 50% neutralizing antibody titer. Logarithmic trendlines were fitted to the data by using Microsoft Excel 2003 (Microsoft Corp., Redmond, WA, USA). Correlation coefficients for LV versus PV₉₀ and LV versus PV₅₀ are 0.69 and 0.78, respectively.

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed February 14, 2005

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention